Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT NHL Vaccine in Relapsed CD20+ NHL
NCT03169790Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of ETBX-061, nogapendekin alfa inbakicept, haNK in non-Hodgkin lymphoma (NHL), sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
ETBX-061nogapendekin alfa inbakicepthaNK
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03169790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169790.